The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
CA 19-9 has been used with questionable accuracy to aid diagnosis of cholangiocarcinoma complicating primary sclerosing cholangitis. We aimed to characterize the test properties of CA 19-9 and of a change in CA 19-9 over time in predicting cholangiocarcinoma. Charts of 208 patients were reviewed. Fourteen patients had cholangiocarcinoma. Median CA 19-9 was higher with cholangiocarcinoma (15 vs. 290 U/ml, p < 0.0001). A cutoff of 129 U/ml provided: sensitivity 78.6%, specificity 98.5%, adjusted positive predictive value 56.6% and negative predictive value 99.4%. The median change over time was 664 U/ml in cholangiocarcinoma compared to 6.7 U/ml in primary sclerosing cholangitis alone (p < 0.0001). A cutoff of 63.2 U/ml for change in CA 19-9 provided: sensitivity 90%, specificity 98% and positive predictive value 42%. Only 2 patients with cholangiocarcinoma were the candidates for curative therapy. In conclusion, the positive predictive value of an elevated CA 19-9 was 56.6%; only advanced cases were detected by this method.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are of limited diagnostic sensitivity and specificity, either alone or in combination.124,126,128,301,302”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [128]
Citations
Cites
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819 · cited 1×
“However, the prevalence of cholangiocarcinoma in autopsies or liver specimens of patients undergoing liver transplantation for PSC is as high as 41%, indicating that the usually quoted figures may underestimate the true prevalence of this cancer (4, 5).”
BackgroundGuidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Khan, S. A., Davidson, B. R., Goldin, R., Pereira, S. P., Rosenberg, W. M. C., Taylor-Robinson, S. D., Thillainayagam, A. V., Thomas, H. C., Thursz, M. R., & Wasan, H. (2002) · Gut · doi:10.1136/gut.51.suppl_6.vi1 · Cited by 648 · cited 2×
“Cholangiocarcinoma may be the initial presentation of PSC and approximately 5% of all cholangiocarcinomas are multifocal (1).”
BackgroundPrimary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481 · cited 1×
“There is some evidence that cholangiocarcinoma is more frequent in smokers (7) and in those with CUC associated with colonic dysplasia or neoplasia (8).”
BackgroundPatel, A. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00744-3 · Cited by 425 · cited 1×
“Previous studies have demonstrated that high CA 19-9 correlates with the risk of developing cholangiocarcinoma in patients with (10, 14–16) or without PSC (17).”
Self-citationCholangiocarcinoma Complicating Primary Sclerosing Cholangitis
ROSEN, C. B., NAGORNEY, D. M., WIESNER, R. H., COFFEY, R. J., & LARUSSO, N. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199101000-00004 · Cited by 391
Self-citationCholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336 · cited 1×
“This finding has not been confirmed by other investigators (16) and was not the aim of our study, as most patients did not have a CEA measured.”
ResultElevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294 · cited 1×
“Levels of CA19-9 show a positive correlation with the bilirubin level or with other markers of cholestasis in patients with obstructive jaundice, making it difficult to interpret an elevated CA19-9 in this setting (20).”
BackgroundBergquist, A., Glaumann, H., Persson, B., & Broomé, U. (1998) · Hepatology · doi:10.1002/hep.510270201 · Cited by 281 · cited 1×
“There is some evidence that cholangiocarcinoma is more frequent in smokers (7) and in those with CUC associated with colonic dysplasia or neoplasia (8).”
BackgroundSerum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279 · cited 1×
“In that study, a value >200 U/ml had sensitivity and specificity of 60 and 90%, respectively, in differentiating PSC versus PSC with cholangiocarcinoma (15).”
Background
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Self-citationCholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Self-citationBanales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationPrimary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
“The utility of CA19-9 is only in combination with other modalities as it lacks sensitivity (low levels may be observed in advanced CCA) and specificity (elevated levels may be observed with cholangitis or other malignancies) (207).”
BackgroundClinical diagnosis and staging of cholangiocarcinoma
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.131 · Cited by 747
“In patients with PSC, the sensitivity and specificity of CA 19-9 is 79% and 98%, respectively, at a serum concentration of >129 U/ml”
BackgroundSelf-citationCholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment†
Blechacz, B., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22310 · Cited by 681
Self-citationBiliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
“Serum carbohydrate antigen (CA)19-9 (with cut-off >129 U/ml) has some added value [III, C] [19].”
BackgroundPrimary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
“lack sensitivity and specificity for the diagnosis of early stage CCA (131).”
Self-citationACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
Self-citationCholangiocarcinoma: Current Knowledge and New Developments
Blechacz, B. (2017) · Gut and Liver · doi:10.5009/gnl15568 · Cited by 485
“In PSC patients, a CA 19-9 cutoff of 129 U/L has a positive predictive value of 57% and a NPV of 99% for CCA.(41) However, CA 19-9 elevations >129 U/L have been reported in 30% to 37% of PSC patients without cholangiocarcinogenesis on long-term follow-up, and its specificity significantly decreases in cholestasis and…”
BackgroundAASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
“Although tests for serum levels of CA 19-9 alone are not sensitive or specific enough to facilitate detection of cholangiocarcinoma, a cut-off of 130 U/mL in the absence of bacterial cholangitis detect cholangiocarcinoma with 79% sensitivity and 98% specificity.(129) The value of measuring serum CA 19-9 to detect asym…”
BackgroundSelf-citationEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationEpidemiology of cholangiocarcinoma
Bergquist, A., & von Seth, E. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.003 · Cited by 400
“CA 19-9 (cutoff 20 IU/mL) Charatcharoenwitthaya [60] 78% 67% 23% 96% CA 19-9 (cutoff 130 IU/mL) Levy [63] 79% 99% 79% 99%”
Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393
Self-citationCholangiocarcinoma—controversies and challenges
Patel, T. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.20 · Cited by 337
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma
Esnaola, N. F., Meyer, J. E., Karachristos, A., Maranki, J. L., Camp, E. R., & Denlinger, C. S. (2016) · Cancer · doi:10.1002/cncr.29692 · Cited by 296
“limited, a markedly elevated serum level may be indicative of unresectable or metastatic disease.(113) Carcinoembry-”
BackgroundCarbohydrate antigen 19-9 — tumor marker: Past, present, and future
Lee, T., Teng, T. Z. J., & Shelat, V. G. (2020) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v12.i12.468 · Cited by 293
Arbelaiz, A., Azkargorta, M., Krawczyk, M., Santos‐Laso, A., Lapitz, A., Perugorria, M. J., Erice, O., Gonzalez, E., Jimenez‐Agüero, R., Lacasta, A., et al. (2017) · Hepatology · doi:10.1002/hep.29291 · Cited by 289
“These data strongly suggest that a proportion of EV present in the serum of CCA patients may be released by tumor cells and may provide specific proteins potentially useful for the diagnosis of CCA.”
BackgroundInfluentialSelf-citationChapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Cholangiocarcinoma: Modern advances in understanding a deadly old disease
Malhi, H., & Gores, G. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.001 · Cited by 269
“Increasing the cutoff to >129 U/ml in patients PSC provided a sensitivity of 78.6%, and improved the specificity to 98.5%, and a positive predictive value of 56.6% [ 56 ].”
BackgroundSelf-citationAabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Rerknimitr, R., Angsuwatcharakon, P., Ratanachu‐ek, T., Khor, C. J. L., Ponnudurai, R., Moon, J. H., Seo, D. W., Pantongrag‐Brown, L., Sangchan, A., Pisespongsa, P., et al. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12128 · Cited by 254
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Li, L., Masica, D., Ishida, M., Tomuleasa, C., Umegaki, S., Kalloo, A. N., Georgiades, C., Singh, V. K., Khashab, M., Amateau, S., et al. (2014) · Hepatology · doi:10.1002/hep.27050 · Cited by 223
“These patients were added because, from a clinical perspective, they present with a clinical picture indistinguishable from CCA.”
InfluentialIntrahepatic Cholangiocarcinoma
El-Diwany, R., Pawlik, T. M., & Ejaz, A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.06.002 · Cited by 214
Blechacz, B. R. A., & Gores, G. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.003 · Cited by 212
“3 U/mL over time provided a sensitivity of 90% and specificity of 98% [67].”
BackgroundSelf-citationCholangiocarcinoma: Update and future perspectives
Gatto, M., Bragazzi, M. C., Semeraro, R., Napoli, C., Gentile, R., Torrice, A., Gaudio, E., & Alvaro, D. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.12.008 · Cited by 188
“8% for CCAdetection [120].”
BackgroundBarr Fritcher, E. G., Kipp, B. R., Halling, K. C., Oberg, T. N., Bryant, S. C., Tarrell, R. F., Gores, G. J., Levy, M. J., Clayton, A. C., Sebo, T. J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.040 · Cited by 182
Self-citationWeismüller, T. J., Wedemeyer, J., Kubicka, S., Strassburg, C. P., & Manns, M. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.020 · Cited by 164
“Also, three current retrospective studies which used higher cut-off values between 100 U/ml and 200 U/ml [124,125,130] found significant correlations with CC.”
BackgroundCancer review: Cholangiocarcinoma
Blechacz, B. R. A., Ghouri, Y. A., & Mian, I. (2015) · Journal of Carcinogenesis · doi:10.4103/1477-3163.151940 · Cited by 154
“A change in the CA 19‐‐9 serum concentration by 63 U/L from baseline carries a sensitivity of 90% with a specificity of 98% for CCA.[54] Early detection of CCA in individuals with PSC is a necessary aspect of their management.”
BackgroundFritcher, E. G. B., Voss, J. S., Brankley, S. M., Campion, M. B., Jenkins, S. M., Keeney, M. E., Henry, M. R., Kerr, S., Chaiteerakij, R., Pestova, E. V., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.046 · Cited by 150
Self-citationFevery, J., Verslype, C., Lai, G., Aerts, R., & Van Steenbergen, W. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9681-4 · Cited by 145
“A recent study by Levy et al. [ 56 ], in 208 patients, documented a respective sensitivity and specificity of CA19-9, at a cutoff of 186 U/ml, of 100% and 94%, respectively.”
BackgroundSinakos, E., Saenger, A. K., Keach, J., Kim, W. R., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.007 · Cited by 142
Self-citationBurnett, A. S., Calvert, T. J., & Chokshi, R. J. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.028 · Cited by 142
Saich, R., & Chapman, R. W. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.331 · Cited by 161
Liang, B., Zhong, L., He, Q., Wang, S.-C., Pan, Z., Wang, T., & Zhao, Y. (2015) · Medical Science Monitor · doi:10.12659/msm.895040 · Cited by 154
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 142
Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis
Huang, Z., & Liu, F. (2014) · Tumor Biology · doi:10.1007/s13277-014-1995-9 · Cited by 139
“Although the serum level of CA19-9 can be elevated in various nonmalignant gastrointestinal diseases [19], its specificity is increased with the increasing cutoff value of CA19-9 [20].”
Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis
Charbel, H., & Al-Kawas, F. H. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0178-8 · Cited by 141
“In a retrospective study of 208 patients with sclerosing cholangitis, including 14 patients with CCA, CA 19-9 had a sensitivity of 79% and a specificity of 98% for diagnosing CCA, with a cut-off value of 129 U/mL [48].”
BackgroundImaging of malignancies of the biliary tract- an update
Hennedige, T. P., Neo, W. T., & Venkatesh, S. K. (2014) · Cancer Imaging · doi:10.1186/1470-7330-14-14 · Cited by 125
Evaluation of indeterminate biliary strictures
Bowlus, C. L., Olson, K., & Gershwin, M. E. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.182 · Cited by 136
Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management
Ilyas, S. I., Eaton, J. E., & Gores, G. J. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.035 · Cited by 122
“Furthermore, examining changes in CA 19-9 over time did not add to the diagnostic yield of a single CA 19-9 value.(59) However, other studies have called into question the high specificity of a CA 19-9 value greater than 129 U/mL.”
Self-citationJhaveri, K. S., & Hosseini‐Nik, H. (2014) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24810 · Cited by 129
“have been 79% sensitive and 98% specific in confirming the diagnosis.(72) But because this tumor marker can be raised following bacterial cholangitis, and is not produced in 7% of the normal population even if they have cholangiocarcinoma,(73) it cannot be used alone as a screening measure.”
BackgroundBowlus, C. L., Lim, J. K., & Lindor, K. D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.011 · Cited by 120
Self-citationIntrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis
Rahnemai‐Azar, A. A., Weisbrod, A. B., Dillhoff, M. E., Schmidt, C. R., & Pawlik, T. M. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2016.12.009 · Cited by 110
Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.013 · Cited by 107
“Cut-off levels of 129 or 100 U/ml detected CCA with high sensitivity (nearly 80%) and specificity (nearly 100%) [81], but only in advanced cases of CCA.”
Diagnosis of cholangiocarcinoma
BEERS, B. E. V. (2008) · HPB · doi:10.1080/13651820801992716 · Cited by 106
“[15] Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD.”
BackgroundCirculating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Rizzo, A., Ricci, A. D., Tavolari, S., & Brandi, G. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20203 · Cited by 109
Fevery, J., Henckaerts, L., Van Oirbeek, R., Vermeire, S., Rutgeerts, P., Nevens, F., & Van Steenbergen, W. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02575.x · Cited by 102
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
Song, J., Li, Y., Bowlus, C. L., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08764-7 · Cited by 112
“When the cut-off is specified as a threefold elevation (129 U/ml), it offers a sensitivity of 79% and a specificity of 99% according to one study [115].”
MethodWannhoff, A., Hov, J. R., Folseraas, T., Rupp, C., Friedrich, K., Anmarkrud, J. A., Weiss, K. H., Sauer, P., Schirmacher, P., Boberg, K. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.005 · Cited by 94
“4% [17].”
Serum Markers of Intrahepatic Cholangiocarcinoma
Malaguarnera, G., Paladina, I., Giordano, M., Malaguarnera, M., Bertino, G., & Berretta, M. (2013) · Disease Markers · doi:10.1155/2013/196412 · Cited by 95
Primary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93
Self-citationLiver Flukes: the Malady Neglected
Lim, J. H. (2011) · Korean Journal of Radiology · doi:10.3348/kjr.2011.12.3.269 · Cited by 86
“CA19-9 was useful for predicting cholangiocarcinoma in patients with primary sclerosing cholangitis, with the sensitivity being 79%, the specificity 99%, the adjusted positive predictive value 57% and the negative predictive value 99% (49).”
BackgroundS2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr. 021-27
Authors, Collaborators:, durch:, E. B., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (. (., (DGIM), D. G. F. I. M., (DCCV), D. M. C. U. V., e.V., D. L., (DEGUM), D. G. F. U. I. D. M., (DGE-BV), D. G. F. E. U. B. V., (DGKJ), D. G. F. K. U. J., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-120199 · Cited by 90
“In der letztgenannten Studie zeigten sich insbesondere deutliche Unterschiede im CA19 – 9 zwischen Patienten mit benignen und malignen Gallenwegstrikturen [582].”
BackgroundCholangiocarcinoma — Current Treatment Options
Friman, S. (2011) · Scandinavian Journal of Surgery · doi:10.1177/145749691110000106 · Cited by 81
Serum Levels of CA19‐9 in patients with nonmalignant respiratory diseases
Kodama, T., Satoh, H., Ishikawa, H., & Ohtsuka, M. (2007) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20136 · Cited by 89
Silakit, R., Loilome, W., Yongvanit, P., Chusorn, P., Techasen, A., Boonmars, T., Khuntikeo, N., Chamadol, N., Pairojkul, C., & Namwat, N. (2014) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.145 · Cited by 80
“Carbohydrate antigen 19-9 (CA-19-9) shows a wide variation in sensitivity (50 to 90%) and specificity (54 to 98%) [5], whereas serum MUC5AC reportedly had 71% sensitivity and 90% specificity for diagnosing CCA [6].”
BackgroundAdvances in the diagnosis, evaluation and management of cholangiocarcinoma
Singh, P., & Patel, T. C. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000218967.60633.64 · Cited by 79
Sandanayake, N. S., Sinclair, J., Andreola, F., Chapman, M. H., Xue, A., Webster, G. J. M., Clarkson, A., Gill, A. J., Norton, I. D., Smith, R. C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.376 · Cited by 86
Fritcher, E. G. B., Voss, J. S., Jenkins, S. M., Lingineni, R. K., Clayton, A. C., Roberts, L. R., Halling, K. C., Talwalkar, J. A., Gores, G. J., & Kipp, B. R. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21331 · Cited by 78
“tive value were calculated for serum CA 19-9 versus 2-year cancer status using a cutoff value of 129 U=mL.(22)”
MethodSelf-citationPrimary sclerosing cholangitis and malignancy
Boberg, K. M., & Lind, G. E. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.002 · Cited by 81
Villard, C., Friis–Liby, I., Rorsman, F., Said, K., Warnqvist, A., Cornillet, M., Kechagias, S., Nyhlin, N., Werner, M., Janczewska, I., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.011 · Cited by 82
Intrahepatic Cholangiocarcinoma: A Malignancy of Increasing Importance
Hammill, C. W., & Wong, L. L. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.04.031 · Cited by 81
Chung, B. K., Karlsen, T. H., & Folseraas, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.020 · Cited by 81
Circulating markers of biliary malignancy: opportunities in proteomics?
Bonney, G. K., Craven, R. A., Prasad, R. K., Melcher, A. F., Selby, P. J., & Banks, R. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70027-5 · Cited by 73
Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis
Ponsioen, C. Y., Lindor, K. D., Mehta, R., & Dimick‐Santos, L. (2018) · Hepatology · doi:10.1002/hep.29882 · Cited by 75
“9) <130 U/mL would make the presence of CCA unlikely.(28) Accounting for CCA development during the course of a clinical trial is complex, given that this could be regarded either as a competing risk or as a clinical outcome and, depending on the mechanism of the drug, could be a primary, secondary, or safety endpoint.”
BackgroundInfluentialSelf-citationAlvaro, D., Macarri, G., Mancino, M. G., Marzioni, M., Bragazzi, M. C., Onori, P., Corradini, S. G., Invernizzi, P., Franchitto, A., Attili, A. F., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00003 · Cited by 78
Yachimski, P., & Pratt, D. S. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31806daf89 · Cited by 75
Goldberg, D., French, B., Thomasson, A., Reddy, R. K., & Halpern, S. D. (2011) · Liver Transplantation · doi:10.1002/lt.22396 · Cited by 66
Biliary Multifocal Chromosomal Polysomy and Cholangiocarcinoma in Primary Sclerosing Cholangitis
Eaton, J. E., Fritcher, E. G. B., Gores, G. J., Atkinson, E. J., Tabibian, J. H., Topazian, M. D., Gossard, A. A., Halling, K. C., Kipp, B. R., & Lazaridis, K. N. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.433 · Cited by 67
Self-citationNew insights on cholangiocarcinoma
Gatto, M., & Alvaro, D. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i3.136 · Cited by 71
Cholangiocarcinoma: Is transplantation an option? For whom?
Gores, G. J., Nagorney, D. M., & Rosen, C. B. B. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.003 · Cited by 63
Self-citationLiver Transplant for Cholangiocarcinoma
Zamora‐Valdés, D., & Heimbach, J. K. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.01.002 · Cited by 61
Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma
Ilyas, S. I., Eaton, J. E., Yang, J. D., Chandrasekhara, V., & Gores, G. J. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1655775 · Cited by 61
Self-citationDiagnosis of Cholangiocarcinoma
Shin, D. W., Moon, S., & Kim, J. H. (2023) · Diagnostics · doi:10.3390/diagnostics13020233 · Cited by 68
Primary sclerosing cholangitis: Diagnosis and management
Charatcharoenwitthaya, P., & Lindor, K. D. (2006) · Current Gastroenterology Reports · doi:10.1007/s11894-006-0067-8 · Cited by 65
Self-citationPrimary sclerosing cholangitis: overview and update
Mendes, F. D., & Lindor, K. D. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.155 · Cited by 62
Self-citationCholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis
Björnsson, E., & Angulo, P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01220.x · Cited by 57
“Thus, the CA 19-9 seems to have unacceptable sensitivity as has recently been shown to be the case in other PSC series (51, 52).”
BackgroundSelf-citationClinical features and management of primary sclerosing Cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3338 · Cited by 64
Self-citationPrimary sclerosing cholangitis
Nguyen, D. L., LaRusso, N. F., & Lazaridis, K. N. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00041-2 · Cited by 57
Self-citationBile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer
Driescher, C., Fuchs, K., Häberle, L., Goering, W., Frohn, L., Opitz, F. V., Haeussinger, D., Knoefel, W. T., Keitel, V., & Esposito, I. (2020) · Cancers · doi:10.3390/cancers13010039 · Cited by 57
Culver, E. L., & Chapman, R. W. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04658.x · Cited by 56
“unresectable CCA which limits its use.(105) Some clinicians screen asymptomatic patients with annual serum Ca19-9 levels and cross-sectional imaging of the hepatobiliary system, although this requires validation.”
Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review
Tshering, G., Dorji, P. W., Chai่jaroenkul, W., & Na‐Bangchang, K. (2018) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.17-0879 · Cited by 64
“Serumbiomarkers such as carbohydrate antigen 19-9 (CA19-9) and cancer antigen 125 (CA125) are being applied inmost routine laboratory tests forCCAdiagnosis.(30,31)”
BackgroundMethodCirculating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer
Chapman, M. H., Sandanayake, N. S., Andreola, F., Dhar, D. K., Webster, G. J. M., Dooley, J. S., & Pereira, S. P. (2011) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(11)60110-2 · Cited by 57
Primary sclerosing cholangitis: A review and update
Tabibian, J. H., & Bowlus, C. L. (2017) · Liver Research · doi:10.1016/j.livres.2017.12.002 · Cited by 65
Liao, Q., Zhao, Y.-P., Yang, Y., Li, L., Long, X. R., & Han, S. (2007) · PubMed · Cited by 58
Impact on follow‐up strategies in patients with primary sclerosing cholangitis
Bergquist, A. M., Weismüller, T. J., Levy, C., Rupp, C., Joshi, D., Nayagam, J. S., Montaño‐Loza, A. J., Lytvyak, E., Wunsch, E., Milkiewicz, P., et al. (2022) · Liver International · doi:10.1111/liv.15286 · Cited by 52
Self-citationMicroRNAs and extracellular vesicles in cholangiopathies
Olaizola, P., Lee, P. Y., Arbelaiz, A., Lapitz, A., Perugorria, M. J., Bujanda, L., & Bañales, J. M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.026 · Cited by 56
Next-Generation Biomarkers for Cholangiocarcinoma
Rodrigues, P. M., Vogel, A., Arrese, M. A., Balderramo, D. C., Valle, J. W., & Bañales, J. M. (2021) · Cancers · doi:10.3390/cancers13133222 · Cited by 56
“In a subgroup of patients with PSC, a CA 19-9 value exceeding 129 U/mL was found to have a specificity and sensitivity of 98 and 79% for CCA diagnosis, respectively [24].”
BackgroundVenkatesh, P. G. K., Navaneethan, U., Shen, B., & McCullough, A. J. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2401-3 · Cited by 49
Liver transplantation for cholangiocarcinoma: Selection is essential for acceptable results
Friman, S., Foss, A. E., Isoniemi, H., Olausson, M., Höckerstedt, K., Yamamoto, S., Karlsen, T. H., Rizell, M., & Ericzon, B. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.533384 · Cited by 55
Lempinen, M., Isoniemi, H., Mäkisalo, H., Nordin, A. J., Halme, L., Arola, J., Höckerstedt, K. A. V., & Stenman, U. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.05.017 · Cited by 47
“With a cut-off value of 100 U/mL, the reported sensitivity ranges between 60% and 89% and specificity between 80% and 97%, respectively [5,15,44].”
BackgroundScreening for Malignancy in Primary Sclerosing Cholangitis (PSC)
Khaderi, S. A., & Sussman, N. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0438-0 · Cited by 48
An update on cancer risk and surveillance in primary sclerosing cholangitis
Horsley‐Silva, J. L., Rodríguez, E. A., Franco, D. L., & Lindor, K. D. (2016) · Liver International · doi:10.1111/liv.13354 · Cited by 46
Self-citationHarder, J., Kummer, O., Olschewski, M., Otto, F., Blum, H. E., & Opitz, O. G. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0155 · Cited by 44
“N 70 43 27 Male, n (%) 33 (47) 21 (49) 12 (44) Female, n (%) 37 (53) 22 (51) 15 (56) Median age (y) 62 63 62 Median CA 19-9 (units/mL) 293 134 412 Tumor grading,* n (%) 1 2 (3) 1 (2) 1 (4) 2 49 (76) 34 (79) 15 (65) 3 14 (20) 8 (19) 6 (27) 4 1 (1) 0 1 (4) Tumor stage, c n (%) II 11 (16) 6 (14) 5 (22) III 16 (24) 11 (26…”
Cholangiocarcinoma: Has There been Any Progress?
Meza–Junco, J., Montaño‐Loza, A. J., Ma, M. M., Wong, W., Sawyer, M. B., & Bain, V. G. (2010) · Canadian Journal of Gastroenterology · doi:10.1155/2010/704759 · Cited by 50
“Levy et al (11) Without primary sclerosing cholangitis (>100 U/mL) 53 >90”
BackgroundInfluentialSerum tumor markers in bile duct cancer – a review
Grunnet, M., & Mau‐Sørensen, M. (2014) · Biomarkers · doi:10.3109/1354750x.2014.923048 · Cited by 43
“Fifteen articles evaluating the use of CA19-9 as a diagnostic marker in BDC were identified in the search performed (Supplementary Table 1; Björnsson et al., 1999; Chalasani et al., 2000; Charatcharoenwitthaya et al., 2008; Fisher et al., 1995; Hultcrantz et al., 1999; Ker et al., 1991; Kim et al., 1999; Levy et al.,…”
Method
Metadata
- Authors
- Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D.
- Affiliations
- University of Florida Health (US)
- Mayo Clinic (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Digestive Diseases and Sciences
- Published
- 2005-09
- Volume
- 50
- Issue
- 9
- Pages
- 1734-1740
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2013099235
- Cited by
- 339
- References
- 23
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 24 · 2020: 13 · 2019: 16 · 2018: 24 · 2017: 22 · 2016: 18 · 2015: 31 · 2014: 22 · 2013: 17 · 2012: 15
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- CA19-9, cholangiocarcinoma, primary sclerosing cholangitis, tumor markers, cancer detection, diagnostic accuracy, serum biomarkers
- MeSH terms
- Bile Duct Neoplasms, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Reference Values, Cholangitis, Sclerosing, Cholangiocarcinoma, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.